Over recent years, targeting the allosteric site of the PTP family of enzymes has proven to be successful.12 In 2017, a cell-permeable small molecule, NAZ2329, was identified to allosterically inhibit both the PTPRZ and PTPRG, thus mitigating the tumorigenicity in glioblastoma cells.13 This allosteric inhibition strategy has since then shown to be extremely promising in glioblastoma drug design. The gene discussed is PTPRG; the disease is glioblastoma.